1. 12.03 ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematological malignancies. (21st September 2022) Authors: Grandclement, C; Estoppey, C; Dheilly, E; Panagopoulou, M; Martini, E; Labanca, V; De Angelis, S; Frei, J; Drake, A; Rubod, A; Gudi, G; Udupa, V; Olsen, J; Giovannini, R; Doucey, M; Feldman, E; Konto, C; Srivastava, A; Zhukovsky, E; Perro, M Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 96PPreliminary pharmacokinetic results from a phase I study of GBR 1302 in patients with HER2 positive cancers. (17th December 2018) Authors: Gudi, G; Ca, V; Gn, S; von Gunten, C; Fluhler, E; Back, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗